DNA vaccination against feline calicivirus infection using a plasmid encoding the mature capsid protein

Vaccine

Volumn 20, Issue 13-14, 2002, Pages 1787-1796

  Sommerville, L M ^a   Radford, A D ^a   Glenn, M ^b   Dawson, S ^a   Gaskell, C J ^a   Kelly, D F ^a   Cripps, P J ^a   Porter, C J ^a   Gaskell, R M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Capsid protein; DNA vaccination; Feline calicivirus

Indexed keywords

CAPSID PROTEIN; CYTOKINE; DNA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALICIVIRUS; CAT; CONTROLLED STUDY; DRUG BIOAVAILABILITY; GENETIC CODE; HETEROLOGOUS EXPRESSION; INFECTION PREVENTION; INOCULATION; NONHUMAN; PLASMID; PRIORITY JOURNAL; RECTUM TEMPERATURE; TEMPERATURE MEASUREMENT; ULCER; VACCINATION; VIRUS INFECTION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; CALICIVIRIDAE INFECTIONS; CALICIVIRUS, FELINE; CAPSID; CAT DISEASES; CATS; FEMALE; MALE; PLASMIDS; VACCINES, DNA; VIRAL VACCINES;

EID: 0037086487     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00024-5     Document Type: Article

References (60)

1. Taxonomy of the Caliciviruses
2. Feline respiratory disease
3. Norwalk group of viruses
4. Rabbit haemorrhagic disease: The new scourge of Oryctolagus cuniculus
5. Vaccination in cats: An update
6. Viral haemorrhagic disease of rabbits: Vaccination and immune response
7. Recombinant feline herpesvirus type I expressing immunogenic proteins inducible virus neutralising antibody against feline calicivirus in cats
8. Vaccine efficacy of recombinant feline herpesvirus type I expressing immunogenic proteins of feline calicivirus in cats
9. Horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease by using a recombinant myxoma virus
10. Expression of the complete capsid and the hypervariable region of feline calicivirus in the baculovirus expression system
11. Self-assembly, antigenicity, and immunogenicity of the rabbit haemorrhagic disease virus (Czechoslovakian strain V-351) capsid protein expressed in baculovirus
12. Immunogenic properties of rabbit haemorrhagic disease virus structural protein VP60 expressed by a recombinant baculovirus: An efficient vaccine
13. A single dose immunisation with rabbit haemorrhagic disease virus major capsid protein produced in Saccharomyces cerevisae induces protection
14. Nucleotide sequence of UK and Australian isolates of feline calicivirus (FCV) and phylogenetic analysis of FCVs
15. Serological relationships among feline caliciviruses
16. Serological classification of feline caliciviruses by plaque-reduction and immunodiffusion
17. Genetic and antigenic heterogeneity among feline calicivirus isolates from distinct disease manifestations
18. Immunisation against feline calicivirus infection
19. Investigation of vaccine reactions and breakdowns after feline calicivirus vaccination
20. Serological analysis of feline calicivirus isolates from the United States and United Kingdom
21. Immunogenicity and safety of an inactivation vaccine for the prevention of rhinotracheitis, caliciviral disease, and panleukopaenia in cats
22. Evaluation of a feline viral rhinotracheitis-feline calicivirus disease vaccine
23. Efficacy of an inactivated feline calicivirus (FCV) vaccine against challenge with United Kingdom field strains and its interaction with the FCV carrier state
24. Mechanisms of persistence of acute and chronic feline calicivirus infections in the face of vaccination
25. Detection of feline calicivirus antigens in the joints of infected cats
26. The use of sequence analysis of a feline calicivirus (FCV) hypervariable region in the epidemiological investigation of FCV related disease and vaccine failures
27. Comparison of serological and sequence-based methods for typing feline calcivirus isolates from vaccine failures
28. Endemic infection of a cat colony with a feline calicivirus closely related to an isolate used in live attenuated vaccines
29. Current understanding of vaccination site-associated sarcomas in the cat
30. The complete nucleotide sequence of feline calicivirus
31. Nucleotide sequence and expression of the capsid protein gene of feline calicivirus
32. Identification and sequence determination of the capsid protein gene of feline calicivirus
33. Analysis of feline calicivirus capsid protein genes: Identification of variable antigenic determinant regions of the protein
34. Cleavage of the feline calicivirus capsid precursor is mediated by a virus-encoded proteinase
35. Location of monoclonal antibody binding sites in the capsid protein of feline calicivirus
36. Mapping of antigenic sites involved in neutralisation on the capsid protein of feline calicivirus
37. The capsid gene of feline calicivirus contains linear B-cell epitopes in both variable and conserved regions
38. Recovery and altered neutralisation specificities of chimeric viruses containing capsid protein domain exchanges from antigenically distinct strains of feline calicivirus
39. Antigen engineering in DNA immunisation
40. Simian immunodeficiency virus DNA vaccine trial in macaques
41. The clinical disease and patterns of excretion associated with three different strains of feline calicivirus
42. Neutralisation patterns among recent British and North American feline calicivirus isolates from different clinical origins
43. A simple method for estimating fifty percent end-points
44. Typing of feline calicivirus isolates from different clinical groups by virus neutralisation tests
45. Direct gene transfer into skeletal muscle in vivo: Factors affecting efficiency of transfer and stability of expression
46. DNA immunisation can stimulate florid local inflammation, and the antiviral immunity induced varies depending on injection site
47. Studies on the role of feline calicivirus in chronic stomatitis in cats
48. Monoclonal antibodies to feline calicivirus
49. Effect of primary-stage feline immunodeficiency virus infection on subsequent feline calicivirus vaccination and challenge in cats
50. DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies
51. Relative potency of cellular and humoral immune responses induced by DNA vaccination
52. Gene vaccination: Plasmid DNA is more than just a blueprint
53. DNA-antiviral vaccines: New developments and approaches - A review
54. A comparison of inactivated feline viral rhinotracheitis and feline caliciviral disease vaccines with live-modified viral vaccines
55. Experimental infections with feline caliciviruses (picornaviruses) in specific-pathogen free cats
56. Experimentally induced feline calicivirus infection: Clinical signs and lesions
57. DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunisation with DNA and viral vectors
58. DNA vaccination: Antigen presentation and the induction of immunity